Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy

Clinical Transplantation

Volumn 12, Issue 3, 1998, Pages 243-249

  Cantarovich, Marcelo ^a   Besner, Jean Guy ^b   Barkun, Jeffrey S ^a   Elstein, Eleanor ^a   Loertscher, Rolf ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Area under the curve heart transplantation; Cyclosporine level 2 h after the morning dose; Cyclosporine trough level; Neoral

Indexed keywords

CREATININE; CYCLOSPORIN A;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; FEMALE; FOLLOW UP; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; CHI-SQUARE DISTRIBUTION; CREATININE; CYCLOSPORINE; DRUG MONITORING; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; PROSPECTIVE STUDIES; RANDOM ALLOCATION; TIME FACTORS;

EID: 0031863345     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. MORRIS PJ Cyclosporine A. Transplantation 1981: 32: 349.
2. KAHAN BD, VAN BURDEN CT, NAN KIN S, et al. Immunopharmacological monitoring of cyclosporin Atreated recipients of cadaveric kidney allografts. Transplantation 1982: 34: 36.
3. KAHAN BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 1985: 40: 457.
4. KAHAN BD, GREVEL J Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988: 46: 631.
5. GREVEL J, WELSH MS, KAHAN BD. Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 1989: 11: 246.
6. GREVEL J, KAHAN BD. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clin Chem 1991: 37: 1905.
7. LINDHOLM A, KAHAN BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993: 54: 205.
8. MILLER LW, O'CONNELL JB. Long-term use of cyclosporine in cardiac transplantation. Transplant Proc 1990: 22: 15.
9. MYERS BD, Ross J, NEWTON L, LUETSCHER J, PERLROTH M. Cyclosporine associated chonic nephopathy. N Engl J Med 1984: 311: 699.
10. MIHATSCH MJ, THIEL G, SPICHTIN HP, et al. Morphological findings in kidney transplant after treatment with cyclosporine. Transplant Proc 1983: 4: 2821.
11. WINKLER M, BRINKMANN C, JOST U, OLDHAFER K, RINGE B, PILCHMAYR R Long-term side-effects of cyclosporine-based immunosuppression in patients after liver transplantation. Transplant Proc 1994: 26: 2679.
12. PALESTINE AG, AUSTIN III HA, BALOW JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986: 314: 1293.
13. GREENBERG A, EGEL JW, THOMPSON ME, et al. Early and late form of cyclosporine nephotoxicity: studies in cardiac transplant patients. Am J Kidney Dis 1987: 9: 12.
14. LEWIS RM, VAN BUREN CT, RADOVANCEVIC B, et al. Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: serial renal function in heart and kidney transplant recipients. J Heart Lung Transplant 1991: 10: 63
15. GONWA TA, MAI ML, PILCHER J, et al. Stability of long-term renal function in heart transplant patients treated with induction therapy and low-dose cyclosporine. J Heart Lung Transplant 1992: 11: 926.
16. WHITE D, ROSE M, WRIGHT L, WALLWORK J, ENGLISH TAH, HUTTER J. Failure of whole blood Cyclosporine levels to provide a reliable measure of immunosuppression in clinical heart and heart-lung transplantation. Transplant Proc 1988: 20: 422.
17. HENRY ML, BOWERS VD, FANNING WJ, SOMMER BG, FERGUSON RM. Cyclosporine levels are not helpful. Transplant Proc 1988: 20: 419.
18. STILLER C, KEOWN P. Failure of 125I-tracer selective monoclonal antibody levels on a whole blood matrix to predict rejection or nephotoxic episodes in renal transplant patients under anti-lymphocyte globulin and prednisone therapy. Transplant Proc 1990: 22: 1253.
19. CANTAROVICH M, FITCHETT D, LATTER D. Cyclosporine trough levels, acute rejection, and renal dysfunction after heart transplantation. Transplantation 1995. 59: 444.
20. CANTAROVICH M, LATTER D, FITCHETT D. Is there a relation between cyclosporine trough levels and endomy-ocardial biopsy score after heart transplantation? Transplant Proc 1994: 26: 2725.
21. JOHNSTON A, SKETRIS JT, MARSDEN CG, et al. A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc 1990: 22: 1345.
22. CANTAROVICH F, BIZOLLON C, CANTAROVICH D, LEFRANÇOIS N, DUBERNARD JM, TRAEGER J. Cyclosporine plasma levels 6 h after oral administration: a useful tool for monitoring therapy. Transplantation 1988: 45: 389.
23. CANTAROVICH F, CANTAROVICH M, TIZADO J, et al. Cyclosporine A long term therapy in autoimmune diseases without nephotoxicity. Nephol Dial Transplant 1990: 5: 658 [Abstract].
24. CANTAROVICH M, DESCHÊNES J. Cyclosporine dose adjustment using levels obtained 6-hours after the morning dose: Effect on side effects in patients with autoimmune diseases. Am J Nephol 1997: 17: 450.
25. CANTAROVICH M, LATTER D, FITCHETT D. Comparison of cyclosporine monitoring with trough levels to levels obtained 6-h after the morning dose in heart transplant patients: a prospective randomized study. Transplant Proc 1997: 29: 602.
26. HOLT DW, MUELLER EA, KOVARICK JM, VAN BREE JB, KUTZ K. The pharmacokinetics of Sandimmune Neoral: a new oral formulation of cyclosporine. Transplant Proc 1994: 26: 2935.
27. KAHAN BD, DUNN J, FITTS C, et al The Neoral formulation: improved correlation between Cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant Proc 1994: 26: 2940.
28. NEUMAYER H, FARBER L, HALLER P, et al. Conversion from Sandimmune to Sandimmune Neoral in patients with stable renal allografts: results after 1 month. Transplant Proc 1994: 26: 2944.
29. POLLARD SG, LODGE JPA. Conversion from Sandimmune to Neoral in stable liver graft recipients. Transplant Proc 1996: 28. 2244.
30. MIKHAIL G, EADON H, LEAVER N, YACOUB M. Use of Neoral in heart transplant recipients. Transplant Proc 1994: 26: 2985.
31. BILLINGHAM M, CARY N, HAMMOND M, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Lung Transplant 1990: 9: 587.
32. ROUBENOFF R, DREW H, MOYER M, PETRI M, WHITING-O'KEEFE Q, HELLEMANN DB. Oral cirnetidine improves the accuracy and precision of creatinine clearance in lupus nephitis. Ann Intern Med 1990: 113: 501.
33. HILBRANDS LB, ARTZ MA, WETZELS JFM, KOENE RAP. Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int 1991: 40: 1171.
34. ROWLAND M, TOZER TN. Clinical Pharmacokinetics: Concepts and Applications. Philadelphia, PA: Lea & Febiger. 1989: 459.
35. WARRENS AN, SALANA A, WATERS JB, LECHER RI. Comparison of Neoral and Sandimmune preparations in renal transplant patients-improved pharmacokinetics with Neoral. Transplant Proc 1996: 28: 2169.
36. KAHAN BD. Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation. Transplant Proc 1996: 28: 2143.
37. KEOWN PA. Use of cyclosporine microemulsion (Neoral) in de novo and stable renal transplantation: clinical impact, pharmacokmetic consequences and economic benefits. Transplant Proc 1996: 28: 2147.
38. KOVARIK JM, MUELLER EA, RICHARD F, et al. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation 1996: 62: 759.
39. KEOWN P, LANDSBERG D, HALLORAN P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1996. 62: 1744.
40. VALANTINE H, HUNT S, GAMBERG P, MILLER J, LUIKART H. Impact of cyclosporine dose on long-term outcome after heart transplantation. Transplant Proc 1994: 26: 2710.
41. RIZEG MN, MASEK MA, BILLINGHAM ME. Acute rejection: significance of elapsed time after transplantation. J Heart Lung Transplant 1994: 13: 862.
42. WINTERS GL, LOH E, SCHOEN FJ. Natural history of focal moderate cardiac allograft rejection. Is treatment warranted? Circulation 1995: 91: 1975.
43. AMANTE AJ, KAHAN BD. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate post-transplant period. Transplant Proc 1996: 28: 2162.